A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

Haruhiko Ogata, T. Matsui, M. Nakamura, M. Iida, M. Takazoe, Y. Suzuki, T. Hibi

Research output: Contribution to journalArticle

291 Citations (Scopus)

Abstract

Background and aims: Immunosuppressive therapy with intravenous ciclosporin is an alternative treatment option to total colectomy for patients with ulcerative colitis (UC), while the benefits of oral administration of tacrolimus are not well defined and are based on reports of several uncontrolled studies. Methods: Patients with refractory active UC were randomly assigned to a high trough concentration (10-15 ng/ml) group (HT group) (n = 21), low trough concentration (5-10 ng/ml) group (LT group) (n = 22), or placebo group (n = 20). Patients received an initial oral dose of 0.05 mg/kg tacrolimus or placebo twice daily. Efficacy was evaluated in 60 patients based on a disease activity index (DAI) score. Fifty eight patients had additional treatment with tacrolimus and were evaluated for efficacy in a 10 week open label extension. Results: An improvement in DAI score (≥4 points, all categories improved) was observed for 68.4% of cases in the HT group compared with 10.0% in the placebo group (p<0.001). In the HT group, 20.0% of patients had clinical remission and 78.9% had mucosal healing. In the open label extension, 55.2% of all patients had an improved DAI score at week 10. Mean dose of prednisolone was reduced from 19.7 mg/day at study entry to 7.8 mg/day at week 10. The incidence of side effects in the HT group was significantly higher than that of the placebo group (p = 0.043). The most common event was mild finger tremor. Conclusions: Our findings demonstrate dose dependent efficacy and safety of oral tacrolimus for remission-induction therapy of refractory UC. The optimal target range appears to be 10-15 ng/ml in terms of efficacy with two week therapy.

Original languageEnglish
Pages (from-to)1255-1262
Number of pages8
JournalGut
Volume55
Issue number9
DOIs
Publication statusPublished - 2006 Sep

Fingerprint

Tacrolimus
Ulcerative Colitis
Placebos
Therapeutics
Remission Induction
Colectomy
Tremor
Immunosuppressive Agents
Prednisolone
Cyclosporine
Fingers
Oral Administration
Safety
Incidence

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Ogata, H., Matsui, T., Nakamura, M., Iida, M., Takazoe, M., Suzuki, Y., & Hibi, T. (2006). A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut, 55(9), 1255-1262. https://doi.org/10.1136/gut.2005.081794

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. / Ogata, Haruhiko; Matsui, T.; Nakamura, M.; Iida, M.; Takazoe, M.; Suzuki, Y.; Hibi, T.

In: Gut, Vol. 55, No. 9, 09.2006, p. 1255-1262.

Research output: Contribution to journalArticle

Ogata, H, Matsui, T, Nakamura, M, Iida, M, Takazoe, M, Suzuki, Y & Hibi, T 2006, 'A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis', Gut, vol. 55, no. 9, pp. 1255-1262. https://doi.org/10.1136/gut.2005.081794
Ogata, Haruhiko ; Matsui, T. ; Nakamura, M. ; Iida, M. ; Takazoe, M. ; Suzuki, Y. ; Hibi, T. / A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. In: Gut. 2006 ; Vol. 55, No. 9. pp. 1255-1262.
@article{edd6811553c84a079113d5d424b78f24,
title = "A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis",
abstract = "Background and aims: Immunosuppressive therapy with intravenous ciclosporin is an alternative treatment option to total colectomy for patients with ulcerative colitis (UC), while the benefits of oral administration of tacrolimus are not well defined and are based on reports of several uncontrolled studies. Methods: Patients with refractory active UC were randomly assigned to a high trough concentration (10-15 ng/ml) group (HT group) (n = 21), low trough concentration (5-10 ng/ml) group (LT group) (n = 22), or placebo group (n = 20). Patients received an initial oral dose of 0.05 mg/kg tacrolimus or placebo twice daily. Efficacy was evaluated in 60 patients based on a disease activity index (DAI) score. Fifty eight patients had additional treatment with tacrolimus and were evaluated for efficacy in a 10 week open label extension. Results: An improvement in DAI score (≥4 points, all categories improved) was observed for 68.4{\%} of cases in the HT group compared with 10.0{\%} in the placebo group (p<0.001). In the HT group, 20.0{\%} of patients had clinical remission and 78.9{\%} had mucosal healing. In the open label extension, 55.2{\%} of all patients had an improved DAI score at week 10. Mean dose of prednisolone was reduced from 19.7 mg/day at study entry to 7.8 mg/day at week 10. The incidence of side effects in the HT group was significantly higher than that of the placebo group (p = 0.043). The most common event was mild finger tremor. Conclusions: Our findings demonstrate dose dependent efficacy and safety of oral tacrolimus for remission-induction therapy of refractory UC. The optimal target range appears to be 10-15 ng/ml in terms of efficacy with two week therapy.",
author = "Haruhiko Ogata and T. Matsui and M. Nakamura and M. Iida and M. Takazoe and Y. Suzuki and T. Hibi",
year = "2006",
month = "9",
doi = "10.1136/gut.2005.081794",
language = "English",
volume = "55",
pages = "1255--1262",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "9",

}

TY - JOUR

T1 - A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

AU - Ogata, Haruhiko

AU - Matsui, T.

AU - Nakamura, M.

AU - Iida, M.

AU - Takazoe, M.

AU - Suzuki, Y.

AU - Hibi, T.

PY - 2006/9

Y1 - 2006/9

N2 - Background and aims: Immunosuppressive therapy with intravenous ciclosporin is an alternative treatment option to total colectomy for patients with ulcerative colitis (UC), while the benefits of oral administration of tacrolimus are not well defined and are based on reports of several uncontrolled studies. Methods: Patients with refractory active UC were randomly assigned to a high trough concentration (10-15 ng/ml) group (HT group) (n = 21), low trough concentration (5-10 ng/ml) group (LT group) (n = 22), or placebo group (n = 20). Patients received an initial oral dose of 0.05 mg/kg tacrolimus or placebo twice daily. Efficacy was evaluated in 60 patients based on a disease activity index (DAI) score. Fifty eight patients had additional treatment with tacrolimus and were evaluated for efficacy in a 10 week open label extension. Results: An improvement in DAI score (≥4 points, all categories improved) was observed for 68.4% of cases in the HT group compared with 10.0% in the placebo group (p<0.001). In the HT group, 20.0% of patients had clinical remission and 78.9% had mucosal healing. In the open label extension, 55.2% of all patients had an improved DAI score at week 10. Mean dose of prednisolone was reduced from 19.7 mg/day at study entry to 7.8 mg/day at week 10. The incidence of side effects in the HT group was significantly higher than that of the placebo group (p = 0.043). The most common event was mild finger tremor. Conclusions: Our findings demonstrate dose dependent efficacy and safety of oral tacrolimus for remission-induction therapy of refractory UC. The optimal target range appears to be 10-15 ng/ml in terms of efficacy with two week therapy.

AB - Background and aims: Immunosuppressive therapy with intravenous ciclosporin is an alternative treatment option to total colectomy for patients with ulcerative colitis (UC), while the benefits of oral administration of tacrolimus are not well defined and are based on reports of several uncontrolled studies. Methods: Patients with refractory active UC were randomly assigned to a high trough concentration (10-15 ng/ml) group (HT group) (n = 21), low trough concentration (5-10 ng/ml) group (LT group) (n = 22), or placebo group (n = 20). Patients received an initial oral dose of 0.05 mg/kg tacrolimus or placebo twice daily. Efficacy was evaluated in 60 patients based on a disease activity index (DAI) score. Fifty eight patients had additional treatment with tacrolimus and were evaluated for efficacy in a 10 week open label extension. Results: An improvement in DAI score (≥4 points, all categories improved) was observed for 68.4% of cases in the HT group compared with 10.0% in the placebo group (p<0.001). In the HT group, 20.0% of patients had clinical remission and 78.9% had mucosal healing. In the open label extension, 55.2% of all patients had an improved DAI score at week 10. Mean dose of prednisolone was reduced from 19.7 mg/day at study entry to 7.8 mg/day at week 10. The incidence of side effects in the HT group was significantly higher than that of the placebo group (p = 0.043). The most common event was mild finger tremor. Conclusions: Our findings demonstrate dose dependent efficacy and safety of oral tacrolimus for remission-induction therapy of refractory UC. The optimal target range appears to be 10-15 ng/ml in terms of efficacy with two week therapy.

UR - http://www.scopus.com/inward/record.url?scp=33747790601&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747790601&partnerID=8YFLogxK

U2 - 10.1136/gut.2005.081794

DO - 10.1136/gut.2005.081794

M3 - Article

C2 - 16484504

AN - SCOPUS:33747790601

VL - 55

SP - 1255

EP - 1262

JO - Gut

JF - Gut

SN - 0017-5749

IS - 9

ER -